Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Crossref DOI link: https://doi.org/10.1007/s40262-016-0453-9
Published Online: 2016-09-15
Published Print: 2017-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Freise, Kevin J.
Jones, Aksana K.
Eckert, Doerthe
Mensing, Sven
Wong, Shekman L.
Humerickhouse, Rod A.
Awni, Walid M.
Salem, Ahmed Hamed
Funding for this research was provided by:
AbbVie
Genentech
License valid from 2016-09-15